# EDGAR Filing Document

**Accession Number:** 0000912544
**File Stem:** 0001493152-26-023227
**Filing Date:** 2026-5
**Character Count:** 68977
**Document Hash:** 30dbd4b5816445beb29241294dce8370
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-023227.hdr.sgml**: 20260515

**ACCESSION NUMBER**: 0001493152-26-023227

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 53

**CONFORMED PERIOD OF REPORT**: 20260331

**FILED AS OF DATE**: 20260515

**DATE AS OF CHANGE**: 20260514

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NovelStem International Corp.
- **CENTRAL INDEX KEY:** 0000912544
- **STANDARD INDUSTRIAL CLASSIFICATION:** RETAIL-RETAIL STORES, NEC [5990]
- **ORGANIZATION NAME:** 07 Trade & Services
- **EIN:** 650385686
- **STATE OF INCORPORATION:** FL
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-14332
- **FILM NUMBER:** 26981147

**BUSINESS ADDRESS:**
- **STREET 1:** 2255 GLADES RD
- **STREET 2:** STE 237 W
- **CITY:** BOCA RATON
- **STATE:** FL
- **ZIP:** 33431
- **BUSINESS PHONE:** 5619988000

**MAIL ADDRESS:**
- **STREET 1:** 2255 GLADES RD
- **STREET 2:** STE 237 W
- **CITY:** BOCA RATON
- **STATE:** FL
- **ZIP:** 33431

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NovelStem International Corp
- **DATE OF NAME CHANGE:** 20220802

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** HOLLYWOOD MEDIA CORP
- **DATE OF NAME CHANGE:** 20001215

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** HOLLYWOOD COM INC
- **DATE OF NAME CHANGE:** 20000511

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 10-Q**

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

**For the quarterly period ended March 31, 2026**

☐ TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _________________ to _________________

Commission file number: 001-14332

**NOVELSTEM INTERNATIONAL CORP.**

(Exact name of registrant as specified in its charter)

<u>Florida</u> <u>65-0385686</u> <br> (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)

<u>7740 Cavern Lane Suite 100, Parkland FL</u> <u>33067</u> <br> (Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code <u>(410) 598-9024</u>

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filed, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ <br> Non-accelerated filer ☒ Smaller reporting company ☒ <br> Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

---

| | |
|:---|:---|
| Class | Outstanding at May 15, 2026 |
| Common Stock, $0.01 par value per share | 49332455 |

---

**NOVELSTEM INTERNATIONAL CORP.**

**Quarterly Report on Form 10-Q**

**for the Quarterly Period Ended March 31, 2026**

**TABLE OF CONTENTS**

---

| | |
|:---|:---|
|  | **PAGE** |
| **[Part I Financial Information](#m_001)** |  |
| [Item 1. Unaudited Condensed Financial Statements:](#m_002) |  |
| [Unaudited Condensed Balance Sheets as of March 31, 2026 and December 31, 2025](#m_003) | 3 |
| [Unaudited Condensed Statements of Operations for the three months ended March 31, 2026 and 2025](#m_004) | 4 |
| [Unaudited Condensed Statements of Changes in Shareholders' Deficit for the three months ended March 31, 2026 and 2025](#m_005) | 5 |
| [Unaudited Condensed Statements of Cash Flows for the three months ended March 31, 2026 and 2025](#m_006) | 6 |
| [Notes to Unaudited Condensed Financial Statements](#m_007) | 7 |
| [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](#m_008) | 15 |
| [Item 3. Quantitative and Qualitative Disclosures About Market Risk](#m_009) | 18 |
| [Item 4. Controls and Procedures](#m_010) | 18 |
| [Part II Other Information](#m_011) |  |
| [Item 1. Legal Proceedings](#m_012) | 18 |
| [Item 1A. Risk Factors](#m_013) | 19 |
| [Item 6. Exhibits](#m_014) | 19 |
| **[Signatures](#m_015)** | 20 |

---

**PART I**

---

| | |
|:---|:---|
| **ITEM 1.** | **UNAUDITED CONDENSED FINANCIAL STATEMENTS** |

---

**NOVELSTEM INTERNATIONAL CORP.**

**CONDENSED BALANCE SHEETS**

---

| | | |
|:---|:---|:---|
|  | **March 31, 2026** | **December 31, 2025** |
| ASSETS |  |  |
| Current assets: |  |  |
| &nbsp;&nbsp;&nbsp;Cash | $89850 | $333 |
| &nbsp;&nbsp;&nbsp;Prepaid expenses | 11062 | 15453 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 100912 | 15786 |
| &nbsp;&nbsp;&nbsp;Total assets | $100912 | $15786 |
| LIABILITIES AND SHAREHOLDERS' DEFICIT |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;Accounts payable | $78389 | $215958 |
| &nbsp;&nbsp;&nbsp;Accrued expenses | 37673 | 37673 |
| &nbsp;&nbsp;&nbsp;Notes payable, including accrued interest | 327266 | 317734 |
| &nbsp;&nbsp;&nbsp;Current portion of long-term notes payable, including accrued interest | 1328061 | 1295405 |
| &nbsp;&nbsp;&nbsp;Bridge loan payable, related party, including accrued interest | 154389 | 171857 |
| &nbsp;&nbsp;&nbsp;Convertible debt, including accrued interest | 121810 | 118814 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | 2047588 | 2157441 |
| Commitments and contingencies (see Note 7) |  |  |
| Shareholders' equity (deficit): |  |  |
| Common stock, $.01 par value, 100,000,000 shares authorized, |  |  |
| 52,767,652 and 50,316,672 shares issued at March 31, 2026 and |  |  |
| December 31, 2025, respectively, and 49,332,455 and 46,881,475 shares |  |  |
| outstanding at March 31, 2026 and December 31, 2025, respectively | 493325 | 468815 |
| Additional paid-in capital | 291795745 | 291570255 |
| Accumulated deficit | (294035992) | (293980971) |
| Treasury stock, at cost, 3,435,197 shares at March 31, 2026 |  |  |
| and December 31, 2025 | (199754) | (199754) |
| &nbsp;&nbsp;&nbsp;Total shareholders' equity (deficit) | (1946676) | (2141655) |
| &nbsp;&nbsp;&nbsp;Total liabilities and shareholders' equity (deficit) | $100912 | $15786 |

---

The accompanying notes are an integral part of these unaudited condensed financial statements.

**NOVELSTEM INTERNATIONAL CORP.**

**CONDENSED STATEMENTS OF OPERATIONS**

**(UNAUDITED)**

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|  | **2026** | **2025** |
| Operating expenses: |  |  |
| &nbsp;&nbsp;&nbsp;General and administrative expenses | $4953 | $94574 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 4953 | 94574 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Loss from operations | (4953) | (94574) |
| Other expenses: |  |  |
| &nbsp;&nbsp;&nbsp;Interest expense | 50068 | 112642 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other expenses | 50068 | 112642 |
| &nbsp;&nbsp;&nbsp;Loss before income taxes | (55021) | (207216) |
| Provision for income tax | - | - |
| &nbsp;&nbsp;&nbsp;Net loss | $(55021) | $(207216) |
| Basic and diluted net income (loss) per share: |  |  |
| &nbsp;&nbsp;&nbsp;Net income (loss) per share - basic | $0.00 | $0.00 |
| Weighted average number of shares outstanding – basic | 47384437 | 46881475 |
| &nbsp;&nbsp;&nbsp;Net income (loss) per share - diluted | $0.00 | $0.00 |
| Weighted average number of shares outstanding - diluted | 47384437 | 46881475 |

---

The accompanying notes are an integral part of these unaudited condensed financial statements.

**NOVELSTEM INTERNATIONAL CORP.**

**CONDENSED STATEMENTS OF SHAREHOLDERS' DEFICIT**

**(UNAUDITED)**

**For the Three Months Ended March 31, 2026:**

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Number of**<br>**Shares** | **Common**<br>**Stock** | **Additional<br> Paid-In**<br>**Capital** | **Accumulated**<br>**Deficit** | **Number of<br> Treasury**<br>**Shares** | **Treasury**<br>**Stock** | **Total<br> Shareholders'**<br>**Deficit** |
| Balance, January 1, 2026 | 46881475 | $468815 | $291570255 | $(293980971) | 3435197 | $(199754) | $(2141655) |
| Net loss |  |  |  | (55021) |  |  | (55021) |
| Stock issued | 2450980 | $24510 | $225490 | $- | - | $- | $250000 |
| Balance, March 31, 2026 | 49332455 | $493325 | $291795745 | $(294035992) | 3435197 | $(199754) | $(1946676) |

---

**For the Three Months Ended March 31, 2025:**

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Number of**<br>**Shares** | **Common**<br>**Stock** | **Additional<br> Paid-In**<br>**Capital** | **Accumulated**<br>**Deficit** | **Number of<br> Treasury**<br>**Shares** | **Treasury**<br>**Stock** | **Total<br> Shareholders'**<br>**Deficit** |
| Balance, January 1, 2025 | 46881475 | $468815 | $290947417 | $(296360853) | 3435197 | $(199754) | $(5144375) |
| Net loss |  |  |  | (207216) |  |  | (207216) |
| Stock-based compensation | - | - | 8741 | - | - | - | 8741 |
| Balance, March 31, 2025 | 46881475 | $468815 | $290956158 | $(296568069) | 3435197 | $(199754) | $(5342850) |

---

The accompanying notes are an integral part of these unaudited condensed financial statements.

**NOVELSTEM INTERNATIONAL CORP.**

**CONDENSED STATEMENTS OF CASH FLOWS**

**(UNAUDITED)**

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|  | **2026** | **2025** |
| Cash flows from operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;Net loss | $(55021) | $(207216) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjustments to reconcile net loss to cash used in operating activities:  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accretion of discount on note payable |  | 43648 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued interest added to notes payable and convertible debt | 49468 | 68448 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation |  | 8741 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change in operating assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, administrative fees |  | 10500 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses | 4391 | (3074) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | (137569) | 35255 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses | - | - |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in operating activities | (138731) | (43698) |
| Cash flows from financing activities: |  |  |
| &nbsp;&nbsp;&nbsp;Proceeds from issuances of short term notes payable | $28248 | $41000 |
| &nbsp;&nbsp;&nbsp;Principal payments, short term notes payable | (50000) |  |
| &nbsp;&nbsp;&nbsp;Proceeds from sale of common stock | 250000 | - |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by financing activities | 228248 | 41000 |
| Net change in cash | 89517 | (2698) |
| Cash at the beginning of the period | 333 | 6099 |
| Cash at the end of the period | $89850 | $3401 |
| Supplemental cash flow information: |  |  |
| Cash paid during the period for: |  |  |
| &nbsp;&nbsp;&nbsp;Interest | $601 | $547 |
| Supplemental Non-Cash Investing and Financing Activities: |  |  |
| &nbsp;&nbsp;&nbsp;Interest added to notes payable and convertible debt | $49468 | $68448 |
| &nbsp;&nbsp;&nbsp;Noncash settlement of accounts payable | $(67500) | $- |

---

The accompanying notes are an integral part of these unaudited condensed financial statements.

**NOVELSTEM INTERNATIONAL CORP.**

**NOTES TO CONDENSED FINANCIAL STATEMENTS**

**(Unaudited)**

**NOTE 1—NATURE OF OPERATIONS**

Description of Business

NovelStem International Corp. ("NovelStem" or the "Company") is a holding company whose principal assets consisted of an approximate 31% equity interest in NewStem Ltd, an Israeli biotech company ("NewStem") and its developed technology, and a 50% equity interest in NetCo Partners ("NetCo"). The interest in NetCo was sold in May 2025 in a noncash transaction which settled significant debt of the Company in the form of a litigation funding agreement. NovelStem was formerly known as Hollywood Media Corp. The Company was incorporated in the State of Florida on January 22, 1993 and changed its name to NovelStem International Corp. in September 2018.

NewStem focused on the development and commercialization of diagnostic technology that can predict patients' anti-cancer drug resistance, allowing for targeted cancer treatments and the potential to reduce resistance to chemotherapy. NewStem was liquidated in August 2025 at which time its intangible assets, primarily in the form of licensing agreements, reverted to the original license holder. The Company retains a right to income from these license agreements.

NetCo is a legacy media business interest which owns "Net Force", a book publishing franchise.

Going Concern, Liquidity and Management's Plans

Since inception, the Company has accumulated a deficit of approximately $294,000,000. The accumulated deficit of the Company subsequent to its business focus shift and name change in September 2018 is approximately $7,355,000 which is comprised primarily of allocated losses from equity method investments and general and administrative costs incurred by the Company.

The Company will need to obtain additional funds to continue its operations. Management's plans with regard to these matters include additional financing and fundraising as well as monetization of the right to intangible assets held from NewStem as well as potential merger or buyout transactions. Specifically, the Company sold its interest in NetCo to its joint venture partner in a transaction that satisfied the related debt (litigation funding agreement). Also, the Company is working with former NewStem management to monetize the technology of NewStem and has an agreement in place to receive up to $3,750,000 of any monetization of these licenses and related intangible assets. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient cash from financing on terms acceptable to the Company, or that the Company will realize any value from the retained interest in intangible assets or technology of NewStem, which was liquidated in August 2025 (see Note 3).

The Company has in place a finance agreement with two individuals who are shareholders and directors under which it borrowed $750,000 and an additional finance agreement with a shareholder under which it borrowed $300,000 for working capital needs (see Note 4). Additionally, the Company entered into additional finance agreements with unrelated parties in December 2023 and April 2024 under which it borrowed an additional $450,000 for working capital needs and to fund NewStem (see Note 4). All funds available pursuant to these agreements have been received. During the three months ended March 31, 2026 and the year ended December 31, 2025, the Company's Executive Chairman advanced a net amount of approximately $140,000 to the Company as an interim bridge loan to fund ongoing expenses. The Company will need to obtain additional funds to continue operations for the next 12 months.

On May 9, 2025, the Company entered into a Settlement Agreement and Release whereby the investment in NetCo was monetized to settle the litigation funding liability to Omni Bridgeway in full. See Note 8.

On March 13, 2026, the Company received $250,000 in exchange for 2,450,980.39 shares of common stock from an unrelated party.

As of the date of this filing, the Company is in negotiations with all debt holders to convert their debt to equity in the Company.

In view of the matters described above, the Company's ability to meet financing requirements is dependent upon the ability to complete additional fundraising or obtain additional financing, and/or monetize the rights to intangible assets from NewStem. These factors, among others, raise substantial doubt about the Company's ability to continue as a going concern. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence.

**NOTE 2—SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

**Basis of Presentation**

The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements. In the opinion of management, the unaudited condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Certain information and footnote disclosures normally included in the Company's annual financial statements prepared in accordance with GAAP have been condensed or omitted. These condensed consolidated financial statement results are not necessarily indicative of results to be expected for the full fiscal year or any future period.

The accompanying unaudited condensed financial statements and related disclosures have been prepared with the presumption that users of the unaudited condensed financial statements have read or have access to the audited financial statements for the preceding fiscal year. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the Company's Form 10-K, which was filed with the United States Securities and Exchange Commission ("SEC") on March 26, 2026, from which the Company derived the balance sheet data at December 31, 2025.

Certain information and footnote disclosures normally included in condensed financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations for interim reporting. The Company believes that the disclosures contained herein are adequate to make the information presented not misleading. These condensed financial statements should be read in conjunction with the Company's Form 10K filed with the Securities and Exchange Commission on March 26, 2026 for the years ended December 31, 2025 and 2024.

**Equity Investments**

Investee companies that are not consolidated, but over which the Company exercises significant influence, are accounted for under the equity method of accounting. Whether or not the Company exercises significant influence with respect to an Investee depends on an evaluation of several factors, including, among others, representation on the investee company's board of directors and ownership level, which is generally a 20% to 50% interest in the voting securities of the Investee company. Under the equity method of accounting, an investee company's accounts are not reflected within the Company's balance sheets or statements of operations; however, the Company's share of the earnings or losses of the investee company would be reflected in the caption "Equity in net income (loss) of investee company" in the statements of operations. The Company's carrying value in an equity method investee company is reflected in the caption "Investment in Investee company" in the Company's Balance Sheets.

The Company reviewed equity investments for impairment on an annual basis, or earlier if events or changes in circumstances indicate that the carrying amounts might not be recoverable.

The Company held a minority investment in an entity, NewStem, which was accounted for pursuant to the equity method of accounting. NewStem was liquidated in August 2025.

Additionally, until May 9, 2025 the Company was a 50% joint venture partner in NetCo which was accounted for pursuant to the equity method of accounting. See Note 3.

**Basic and Diluted Net Loss Per Share**

Basic net income (loss) per share is computed by dividing the net income (loss) by the weighted average number of shares outstanding during the period, excluding treasury stock. Diluted net loss per share is computed by dividing the net loss by the weighted average number of shares outstanding plus the dilutive potential of common shares which would result from the exercise of stock options and warrants or the conversion of debt. The dilutive effects of stock options and warrants are excluded from the computation of diluted net income (loss) per share if the effect of doing so would be antidilutive.

The following data represents the amounts used in computing earnings per share and the effect on loss and the weighted average number of shares of dilutive potential common stock (unaudited):

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|  | **2026** | **2025** |
| Net loss available to common shareholders | $(55021) | $(207216) |
| Weighted average shares outstanding: |  |  |
| -Basic | 47384437 | 46881475 |
| Basic net income (loss) per share | $0.00 | $0.00 |
| Net income (loss) attributable to common shareholders | $(55021) | $(207216) |
| Effect of dilutive securities: |  |  |
| &nbsp;&nbsp;&nbsp;Convertible debt, interest | - | - |
| Net income (loss) attributable to common shareholders | $(55021) | $(207216) |
| Weighted average shares outstanding: |  |  |
| -Basic | 47384437 | 46881475 |
| Add: Convertible debt | - |  |
| Add: Stock options | - | - |
| -Diluted | 47384437 | 46881475 |
| Diluted net loss per share | $0.00 | $0.00 |

---

Options and warrants excluded from the computation of earnings per share (unaudited):

SCHEDULE OF OPTIONS AND WARRANTS EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|  | **2026** | **2025** |
| Warrants |  | 3000000 |
| Convertible debt | 937000 | 858493 |
| Stock options | 6060000 | 6360000 |

---

**NOTE 3—EQUITY METHOD INVESTMENTS**

**Investment in NewStem**

The Company held a 31% interest in NewStem until its liquidation in August 2025.

The Company accounted for its investment in NewStem under the equity method. NewStem was a development stage company which incurred losses from inception and generated only minimal revenues under a licensing agreement.

The Company assessed its investment in NewStem for impairment on an annual basis or more frequently if indicators of impairment existed. During the year ended December 31, 2024, indicators of impairment became evident due to the inability of NewStem to raise funds. Due to the inability to raise funds, NewStem was unable to continue operations and was liquidated. The intangible assets of NewStem, including license agreements (the "License"), have reverted to the licensor, Yissum (the commercial division of Hebrew University). The Company has reached an agreement with Yissum regarding the potential monetization of these intangible assets which provides for funds to be received by the Company in the event of re-licensing or monetizing the licenses or related technology developed by NewStem. Due to the current uncertainty of the recovery of any value from these intangible assets and the liquidation status of NewStem, the Company fully impaired the investment in NewStem during the year ended December 31, 2024. On August 14, 2025, the Company received $5,432 from NewStem upon the final closing of their accounts and in October 2025, the Company wrote off all asset accounts and the related impairment and ceased accounting for NewStem.

**Investment in NetCo**

As of March 31, 2025, NovelStem owned a 50% interest in NetCo, a joint venture that owns the Net Force publishing franchise. On May 9, 2025, the Company entered into a Settlement Agreement and Release whereby the investment in NetCo was sold to the Company's JV partner for $1,300,000 to settle the related litigation funding liability to Omni Bridgeway in full. This transaction was fully consummated as funds were received by Omni Bridgeway from CP Partners pursuant to the terms of the agreement.

The following table represents the Company's investment in NetCo:

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended March 31, 2026** | **Year Ended<br> December 31, 2025** |
|  | **(Unaudited)** | |
| Investment in NetCo, beginning | $- | $128240 |
| Allocation of net income (loss) from NetCo |  | 640 |
| Distribution from NetCo |  | (640) |
| Sale of ownership interest in NetCo | - | (128240) |
| Investment in NetCo, ending | $- | $- |

---

The results of operations of the Company's investment in NetCo is summarized below (unaudited):

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|  | **2026** | **2025** |
| Condensed income statement information: |  |  |
| Net sales | $- | $- |
| Gross margin | $- | $(79) |
| Net loss | $- | $(154) |
| Company's allocation of net loss from NetCo | $- | $(77) |

---

The Company did not record the allocated loss of $77 during the three months ended March 31, 2025 due to the immateriality of the amount and the sale of our interest in NetCo for $1,300,000 and dissolution of the joint venture.

**NOTE 4—NOTES PAYABLE**

In December 2023, the Company entered into two short-term notes payable with unrelated parties, Hewlett Fund and AIGH Investment Partners, LLC. The notes are for $125,000 each, for a total of $250,000 in borrowings utilized for the funding of NewStem. The notes bear interest at 12% per annum and originally matured on December 21, 2024. The maturity date for both notes has been extended until June 30, 2026 at which time all principal and accrued interest are due and payable. The note agreements include a provision whereby, in the event of a capital raise transaction by the Company, the note holders would be entitled to participate in the transaction in an amount equal to 133% of the amounts owed on the note agreements at the closing of the transaction. Interest expense related to these notes was $9,532 and $7,397, respectively, for the three months ended March 31, 2026 and 2025.

Long-term notes payable are summarized as follows:

---

| | | |
|:---|:---|:---|
|  | **As of** | **As of** |
|  | **March 31, 2026** | **December 31, 2025** |
|  | **(Unaudited)** | |
| **Notes payable related parties:** |  |  |
| &nbsp;&nbsp;&nbsp;Notes payable director and Executive Chairman | $821766 | $821766 |
| &nbsp;&nbsp;&nbsp;Accrued interest added to note balance | 153181 | 129208 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total notes payable director and Executive Chairman | 974947 | 950974 |
| &nbsp;&nbsp;&nbsp;Note payable shareholder, principal amount | 300000 | 300000 |
| &nbsp;&nbsp;&nbsp;Accrued interest added to note balance | 53114 | 44431 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total note payable shareholder | 353114 | 344431 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total notes payable | 1328061 | 1295405 |
| &nbsp;&nbsp;&nbsp;Less current portion | (1328061) | (1295405) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Long-term notes payable | $- | $- |

---

In May 2022, the Company entered into note agreements with Jan Loeb, our Executive Chairman and Jerry Wolasky, a shareholder and member of the Board, to borrow up to an aggregate of $600,000 for working capital needs. The note agreements were amended in March 2024 to increase the total borrowing to $650,000 and extend the maturity date. The note agreements were refinanced in August 2024 providing for total borrowings of $750,000. The agreements provide for interest at a rate of 10% per annum and matured December 31, 2025. As of the date of these financial statements, the full amount of $750,000 has been funded pursuant to these agreements and the maturity dates have been extended to June 30, 2026. Interest expense related to these agreements was $23,973 and $20,263 for the three months ended March 31, 2026 and 2025, respectively.

On May 5, 2023, the Company entered into a long-term note payable with a shareholder for $300,000 in financing to be funded $150,000 at inception and $150,000 in October 2023. This note bore interest at zero percent (0%) and originally matured on May 5, 2025. The note included a guarantee which was identified as an embedded derivative with a fair value of a liability of $650,000 on March 31, 2025 which was reported separately on the balance sheet. The fair value of the note exceeded the proceeds, and the note was discounted at inception so that the net liability was the fair value of the derivative. Accretion of the note discount of $43,648 has been reflected as part of interest expense in the statement of operations for three months ended March 31, 2025. This note agreement was amended in May 2025 to provide for a fixed amount of interest of $36,000 in lieu of the guarantee. This amendment, which was determined to be accounted for pursuant to the provisions of ASC 470 for troubled debt restructurings with related parties, ended the discounting of the note and the separate recording of an embedded derivative, as the note now bears interest and contains no identifiable embedded derivative. As such, the relief of the guarantee was recorded as an adjustment to equity and interest expense of $36,000 was accrued and treated as a reduction to equity. Beginning October 1, 2025, the note began to bear interest at a rate of 10% per annum. The note matures on December 31, 2026. Interest expense related to this note was $8,683 for the three months ended March 31, 2026.

**Note Payable Litigation Funding Agreement**

On February 11, 2022, the Company entered into a nonrecourse litigation funding agreement (the "Agreement") with Omni Bridgeway (Fund 4) Invt. 3 L.P. ("Omni") related to a previously settled arbitration. The Agreement provided for Omni to fund all costs related to the arbitration up to $1,000,000 in exchange for an assignment of a certain portion of rights to and interest in claims related to this arbitration. The agreement provided for specific calculations of the portion of any claims collected to be received by Omni with the remainder collectible by the Company. Additionally, the agreement provided for repayment of funded costs pursuant to the same multiple calculations in the event of a favorable outcome that does not include the collection of claims.

During July 2023, the arbitration was settled. As a result of the ruling, the liability became probable and reasonably estimable, and the Company recorded the full liability due to Omni as of December 31, 2023. This liability consisted of expenses funded by Omni of $933,065, including $310,000 advanced for working capital, and related fees or investment return to Omni calculated as contractual multiples of funding totaling $1,886,131 for a total liability of $2,819,196. This agreement bore interest at 5% per annum beginning January 2024 and was payable in full on January 10, 2025. The Company accrued interest related to the Agreement of $37,400 during the three months ended March 31, 2025.

The Company began negotiations for settlement of this Agreement during 2024 and on May 9, 2025, the Company entered into a Settlement Agreement and Release with our JV partner in NetCo, C.P. Group, and Omni whereby our interest in NetCo was sold in exchange for funds of $1,300,000 which were paid directly to Omni by CP Group in full settlement and release of all liabilities related to the Litigation Funding Agreement.

**Bridge Loan**

In February 2025, Jan Loeb, Executive Chairman, began advancing funds to the Company for operating expenses in the form of an interim bridge loan until alternate funding sources can be found. The bridge loan matured on December 31, 2025 and has been extended to June 30, 2026. The Company is accruing interest at 10% per annum for these advances. The total advanced during the three months ended March 31, 2026 and 2025 was $28,248 and $41,000, respectively. Additionally, $50,000 was repaid during the three months ended March 31, 2026. Interest expense related to these advances was $4,284 and $430, respectively, during the three months ended March 31, 2026 and 2025.

**Convertible Debt**

In April 2024, the Company borrowed $100,000 from unrelated parties pursuant to convertible debt agreements accounted for as debt. These agreements bear interest at 10% per annum and matured on December 30, 2025. The maturity dates have been extended to June 30, 2026. The unpaid principal balance of these notes and any accrued interest may be converted into shares of the Company's common stock at a conversion price of $0.13 per share. Interest accrued related to these agreements was $2,995 and $2,958, respectively, during the three months ended March 31, 2026 and 2025.

**NOTE 5—EQUITY**

(a) General

At March 31, 2026 the Company had issued 52,767,652 shares and had outstanding 49,332,455 shares of its stock outstanding with a par value of $0.01 per share.

At December 31, 2025 the Company had issued 50,316,672 shares and had 46,881,475 shares of its common stock outstanding with a par value of $0.01 per share.

Holders of outstanding common stock are entitled to receive dividends when, as and if declared by the Board, and to share ratably in the assets of the Company legally available for distribution in the event of liquidation, dissolution or winding up of the Company.

(b) Summary Employee Option Information

The Company's stock option plan provides for the grant to officers, directors, third party contractors and other future key employees of options to purchase shares of common stock. The purchase price may be paid in cash or, if the option is "in-the-money", it is automatically exercised "net". In a net exercise of an option, the Company does not require a payment of the exercise price of the option from the optionee but reduces the number of shares of common stock issued upon the exercise of the option by the smallest number of whole shares that has an aggregate fair market value equal to or in excess of the aggregate exercise price for the option shares covered by the option exercised. Each option is exercisable to one share of the Company's common stock. Most options expire within six years from the date of the grant and generally vest on the first anniversary date of their issuance. Pursuant to the Equity Incentive Plan the Company's board of directors approved on November 12, 2018, an aggregate of 6,360,000 options have been issued to directors and investor relations professionals of which 300,000 have expired and 6,060,000 remain outstanding.

No options were issued during the three months ended March 31, 2026 and 2025.

The expected term of the options represents an estimate of the length of time until the expected date of exercising the options. Options granted have a maximum life of 7 years. With respect to determining expected exercise behavior, the Company has grouped its option grants into certain groups to track exercise behavior and establish historical rates. The Company estimated volatility by considering historical stock volatility over the expected term of the option. The risk-free interest rates are based on the U.S. Treasury yields for a period consistent with the expected term. The dividend yield of 0% is based on the Company's history and expectation of dividend payout. The Company has not paid and does not anticipate paying dividends in the near future.

(c) Summary Option Information

A summary of the Company's option plans for the three months ended March 31, 2026, is presented below (unaudited):

---

| | | |
|:---|:---|:---|
|  | Number<br>of<br>Options<br>(in shares) | Weighted<br>Average<br>Exercise<br>Price |
| Outstanding, December 31, 2025 | 6060000 | $0.137 |
| Granted | - | - |
| Outstanding, March 31, 2026 | 6060000 | $0.137 |
| Exercisable, March 31, 2026 | 6060000 | $0.137 |

---

Stock-based compensation expense was approximately $9,000 in the three months ended March 31, 2025. There was no such stock-based compensation expense during the three months ended March 31, 2026.

(d) Warrants

The Company had issued warrants at exercise prices equal to or greater than the market value of the Company's common stock at the date of issuance. All warrants expired on June 28, 2025.

**NOTE 6—INCOME TAXES**

The Company's income tax expense and effective tax rates for the three months ended March 31, 2026 and 2025 were as follows:

SCHEDULE OF INCOME TAX EXPENSE AND EFFECTIVE TAX RATES

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|  | **2026** | **2025** |
| Loss before income taxes | $(55021) | (207216) |
| Income tax expense |  |  |
| Effective tax rate | 0.00% | 0.00% |

---

The Company's income tax provision differs from the expense that would result from applying statutory rates to income (loss) before taxes. A reconciliation of the provision (benefit) for income taxes with amounts determined by applying the statutory U.S. federal income tax rate to income before income taxes is as follows (unaudited):

SCHEDULE OF INCOME BEFORE INCOME TAXES

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|  | **2026** | **2026** | **2025** | **2025** |
|  | **Amount** | **Tax Rate** | **Amount** | **Tax Rate** |
| Computed tax at the federal statutory rate of 21% | $(11554) | 21.00% | $(43515) | 21.00% |
| Increase (decrease) in income tax rate resulting from: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Nondeductible/nontaxable items |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest- related party, note discount and limitation | 10514 | (19.11)% |  | 0.00% |
| &nbsp;&nbsp;&nbsp;State income taxes, net of federal income tax benefit | (2393) | 4.35% | (9004) | 4.35% |
| &nbsp;&nbsp;&nbsp;Change in federal valuation allowance | 3433 | (6.24)% | 52519 | (25.35)% |
| &nbsp;&nbsp;&nbsp;Total provision for income tax | $- | 0.00% | $- | 0.00% |

---

**NOTE 7—SUBSEQUENT EVENTS**

The Company evaluated subsequent events through the date these financial statements were available to be issued and filed with the SEC.

**NOVELSTEM INTERNATIONAL CORP.**

---

| | |
|:---|:---|
| **ITEM 2.** | **MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS** |

---

Statements in the following discussion and throughout this Form 10-Q that are not historical in nature are "forward-looking statements." You can identify forward-looking statements by the use of words such as "expect," "anticipate," "estimate," "may," "will," "should," "intend," "believe," and similar expressions. Although we believe the expectations reflected in these forward-looking statements are reasonable, such statements are inherently subject to risk and we can give no assurances that our expectations will prove to be correct. Actual results could differ from those described in this Form 10-Q because of numerous factors, many of which are beyond our control. We undertake no obligation to update these forward-looking statements to reflect events or circumstances after the date of this Form 10-Q or to reflect actual outcomes.

**Overview**

We are a development stage company and reported net losses of approximately $55,000 and $207,000 for the three months ended March 31, 2026 and 2025, respectively. We had current assets of approximately $101,000 and current liabilities of $2,048,000 as of March 31, 2026. As of December 31, 2025, our current assets and current liabilities were approximately $16,000 and $2,157,000, respectively. The increase in current assets is due to the sale of equity securities during the three months ended March 31, 2026. The decrease in current liabilities is primarily due to the reduction of accounts payable and the repayment of $50,000 on short-term borrowings as offset by interest accrued on debt and advances on short-term borrowings to fund operating expenses.

We have prepared our financial statements for the three months ended March 31, 2026, assuming that we will continue as a going concern. Our continuation as a going concern is dependent upon improving our profitability and the continuing financial support from our shareholders as well as Yissum's ability to successfully commercialize the License. Our sources of capital in the past have included the sale of equity securities, which include common stock sold in private transactions, and related party debt as well as debt from unrelated parties. During 2025 we entered into a bridge loan agreement with our Executive Chairman to obtain funding for current operating expenses and in March 2026 we issued common stock in exchange for $250,000 in a private transaction.

**RESULTS OF OPERATIONS**

The following discussion of our financial condition and results of operations should be read in conjunction with our financial statements and the related notes thereto and other financial information appearing elsewhere in this Form 10-Q. In the discussion below, general and administrative expenses are referred to as "G&A expenses".

---

| | | | |
|:---|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|  | **2026** | **2025** | **Change** |
| Operating expenses: |  |  |  |
| &nbsp;&nbsp;&nbsp;G&A expenses | 4953 | 94574 | (89621) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 4953 | 94574 | (89621) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Loss from operations | (4953) | (94574) | 89621 |
| Other expenses: |  |  |  |
| &nbsp;&nbsp;&nbsp;Interest expense | 50068 | 112642 | (62574) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other expenses | 50068 | 112642 | (62574) |
| &nbsp;&nbsp;&nbsp;Net loss | $(55021) | $(207216) | $152195 |

---

We are a holding company whose primary asset currently is our right to the monetization of the former NewStem license now held by Yissum. We currently conduct no other business and as a result, we have no operating revenue or cost of revenue.

The Company incurs general and administrative ("G&A") expenses primarily related to professional fees, insurance and stock-based compensation. We incurred G&A expenses of approximately $5,000 and $95,000 for the three months ended March 31, 2026 and 2025, respectively. Specifically, professional fees decreased by approximately $69,000 in the three months ended March 31, 2026 as compared to the three months ended March 31, 2025, primarily due to a decrease in accounting fees of approximately $4,100 and the write off of approximately $67,500 in prior years legal fees due to the settlement of outstanding fees at a discount, netted with an increase in audit fees of approximately $1,600 combined with other increases of approximately $1,000. We incurred a bad debt expense during the three months ended March 31, 2025 of approximately $9,500 for the write off of uncollectible administrative fees. We had reductions in stock compensation of approximately $8,700 as no options were issued during 2025 and previously issued stock options were fully expensed during 2025. Other miscellaneous G&A expenses decreased by approximately $2,000.

Interest expense decreased by approximately $63,000 in the three months ended March 31, 2026 as compared to the three months ended March 31, 2025 primarily due to the settlement of the litigation funding agreement on May 9, 2025.

The Company has recorded no income tax expense as we have incurred operating losses and all deferred tax assets are fully offset by an income tax valuation allowance.

**Liquidity and Capital Resources**

We have not paid dividends on our common stock since our name change and business focus shift in 2018. Our present policy is to apply cash to debt service, acquisitions or expansion; consequently, we do not expect to pay dividends on common stock in the foreseeable future.

The Company will need to obtain additional funds to continue its operations. Management's plans with regard to these matters include fundraising until our interest in NewStem's technology via monetization of the License is profitable. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient cash from financing on terms acceptable to the Company, or that NewStem's technology will be monetized and become profitable.

The Company has in place note agreements entered into during 2022 with Jan Loeb, our Executive Chairman and Jerry Wolasky, a member of the Board, to borrow up to an aggregate of $750,000 for working capital needs. The agreements provide for interest at a rate of 10% per annum and mature June 30, 2026. As of the date of this Quarterly Report, the full amount of $750,000 has been funded pursuant to these agreements.

During the year ended December 31, 2023, the Company entered into a note agreement with a shareholder to borrow $300,000 for continued working capital. This note bore interest at zero percent (0%) and matured on May 5, 2025. The note included a guarantee which was identified as an embedded derivative with a fair value of a liability of $650,000 at March 31, 2025. This note was amended in May 2025 to provide for fixed interest, remove the guarantee and extend the maturity date to September 30, 2025. This note was amended for a second time in October 2025 to extend the maturity date to December 31, 2026.

In December 2023, the Company entered into two short-term notes payable with unrelated parties for a total of $250,000 in borrowings utilized for the funding of NewStem. The notes bear interest at 12% per annum and mature June 30, 2026 at which time all principal and accrued interest are due and payable. The note agreements include a provision whereby, in the event of a capital raise transaction by the Company, the note holders would be entitled to participate in the transaction in an amount equal to 133% of the amounts owed on the note agreements at the closing of the transaction.

In April 2024, the Company borrowed $100,000 from unrelated parties pursuant to convertible debt agreements accounted for as debt. The notes bear interest at 10% per annum and mature June 30, 2026.

In February 2025, the Company entered into a bridge loan agreement with the Executive Chairman to fund working capital until such time as additional funding can be obtained. Advances from on this note were approximately $28,000 and $41,000 during the three months ended March 31, 2026 and 2025, respectively. The Company repaid $50,000 on this note during the three months ended March 31, 2026. The note bears interest at 10% per annum and matures June 30, 2026

On May 9, 2025 the Company sold its interest in NetCo to its JV partner for $1,300,000 which was paid directly to Omni Bridgeway in full settlement of all liabilities related to the litigation funding agreement totaling $2,959,625.

On March 13, 2026, the Company received $250,000 in exchange for 2,450,980.39 shares of common stock from an unrelated party.

*Net Cash Used In Operating Activities.*

For the three months ended March 31, 2026, net cash used in operating activities was approximately $139,000, which consisted primarily of a net loss of approximately $55,000, offset by interest added to notes payable of approximately $49,000. Additionally, cash was used in operations related to a decrease in accounts payable of approximately $137,000 offset by a decrease in current assets of approximately $4,000.

For the three months ended March 31, 2025, net cash used in operating activities was approximately $44,000, which consisted primarily of a net loss of approximately $207,000, offset by accretion of discount on notes payable of approximately $43,000, stock-based compensation of approximately $9,000 and interest added to notes payable of approximately $68,000. Additionally, cash was used in operations related to an increase in current assets of approximately $8,000 and a net increase in total accrued liabilities and accounts payables of approximately $35,000.

*Net Cash Used In Investing Activities.*

No net cash was used in investing activities during the three months ended March 31, 2026 and 2025.

*Net Cash Provided By Financing Activities.*

For the three months ended March 31, 2026, net cash provided by financing activities was $228,000, consisting of short-term borrowings from the Executive Chairman of approximately $28,000, proceeds from the issuance of common stock of $250,000 offset by repayment of $50,000 in short-term borrowings from the Executive Chairman.

For the three months ended March 31, 2025, net cash provided by financing activities was $41,000, consisting of short-term borrowings from the Executive Chairman.

---

| | |
|:---|:---|
| **ITEM 3.** | **QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK** |

---

This section is not applicable.

---

| | |
|:---|:---|
| **ITEM 4.** | **CONTROLS AND PROCEDURES** |

---

Our Principal Executive Officer and Chief Financial Officer conducted an evaluation of our controls and procedures. We have identified material weaknesses in our internal control and procedures and internal control over financial reporting. If not remediated, our failure to establish and maintain effective disclosure controls and procedures and internal control over financial reporting could result in material misstatements in our financial statements and a failure to meet our reporting and financial obligations, each of which could have a material adverse effect on our financial condition and the trading price of our common stock.

Maintaining effective internal control over financial reporting and effective disclosure controls and procedures are necessary for us to produce reliable financial statements. We have re-evaluated our internal control over financial reporting and our disclosure controls and procedures and concluded that they were not effective as of March 31, 2026 and we concluded there was a material weakness in the design of our internal control over financial reporting as it relates to insufficient resources to employ proper segregation of duties over the processing of transactions and financial reporting.

A material weakness is defined as a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.

**Changes in Internal Control Over Financial Reporting**

There was no change in our internal control over financial reporting (as such term is defined in Rule 13a-15(f) under the Exchange Act) during the period covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

**PART II**

---

| | |
|:---|:---|
| **ITEM 1.** | **LEGAL PROCEEDINGS**<br>|

---

The Company had no legal proceedings during the reporting period.

---

| | |
|:---|:---|
| **ITEM 1A.** | **RISK FACTORS** |

---

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information under this item.

---

| | |
|:---|:---|
| **ITEM 2.** | **UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS** |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Not
 applicable.

(b) Not
 applicable.

(c) Not
 applicable.

---

| | |
|:---|:---|
| **ITEM 3.** | **DEFAULTS UPON SENIOR SECURITIES** |

---

Not applicable.

---

| | |
|:---|:---|
| **ITEM 4.** | **MINE SAFETY DISCLOSURES** |

---

Not applicable.

---

| | |
|:---|:---|
| **ITEM 5.** | **OTHER INFORMATION** |

---

None.

---

| | |
|:---|:---|
| **ITEM 6.** | **EXHIBITS** |

---

---

| | |
|:---|:---|
| #10.15 | [Loan Extension Bridge Note to Jan Loeb](ex10-15.htm) |
| #10.16 | [Loan Extension Related Party Note to Jan Loeb](ex10-16.htm) |
| #10.17 | [Loan Extension Related Party Note to Jerry Wolasky](ex10-17.htm) |
| #31.1 | [Certification of Principal Executive Officer and Executive Chairman pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](ex31-1.htm) |
| #31.2 | [Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](ex31-2.htm) |
| #32.1 | [Certification of Principal Executive Officer and Executive Chairman pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](ex32-1.htm) |
| #32.2 | [Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](ex32-2.htm) |

---

104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

# This exhibit is filed or furnished herewith.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **NOVELSTEM INTERNATIONAL CORP.** | **NOVELSTEM INTERNATIONAL CORP.** |
| Date: May 15, 2026 | By: | */s/ Jan Loeb* |
|  | Name: | Jan Loeb |
|  | Title: | Executive Chairman |

---

## Exhibit 10.15

**Exhibit 10.15**

**LOAN EXTENSION AGREEMENT**

**1.** **THE PARTIES.** This Loan Extension Agreement ("Agreement") made February 15, 2026
 between:

Borrower/Issuer: NovelStem International Corp. Ltd., with a mailing address of 2255 Glades Road, Suite 221A, Boca Raton, FL ("Borrower or Issuer") and

Lender/Holder: Jan Loeb, with a mailing address of 7740 Cavern Lane, Attn: Jan Loeb, Parkland FL 33067 ("Lender or Holder").

HEREINAFTER the Borrower and Lender shall be referred to together as the "Parties" and in consideration of the covenants herein contained agree as follows:

2. **ORIGINAL NOTE**. This Agreement is amending a note that exists between the Parties signed on May
 16, 2025 for the sum of Ninety-One Thousand Dollars ($91,000) plus additional advances and
 maturing on December 30, 2025 ("Original Note"). Such additional advances between
 May 16, 2025 and February 15, 2026 bring the principal advances through the date of this
 extension to a total of One Hundred Eighty-Six Thousand Eight Hundred Sixty-Seven Dollars
 ($186,867).

3. **EXTENSION**.
 Under this Agreement, the Parties agree to extend the maturity date as stated in the Original
 Note to June 30, 2026 ("Extension Date").

4. **ADDITIONAL TERMS**. The Parties agree that all other terms and conditions stated in the Original Note
 shall remain in full force and effect and that there are no additional amendments.

IN WITNESS WHEREOF, the Parties have indicated their acceptance of the terms of this Agreement by their signatures below on the dates indicated.

---

| | |
|:---|:---|
| **Borrower's Signature:** | **Date:** |

---

---

| | |
|:---|:---|
| **Lender's Signature:** | **Date:** |

---

## Exhibit 10.16

**Exhibit 10.16**

**LOAN EXTENSION AGREEMENT**

**1.** **THE PARTIES.** This Loan Extension Agreement ("Agreement") made February 15, 2026
 between:

Borrower/Issuer: NovelStem International Corp. Ltd., with a mailing address of 2255 Glades Road, Suite 221A, Boca Raton, FL ("Borrower or Issuer") and

Lender/Holder: Jan Loeb, with a mailing address of 7740 Cavern Lane, Attn: Jan Loeb, Parkland FL 33067 ("Lender or Holder").

HEREINAFTER the Borrower and Lender shall be referred to together as the "Parties" and in consideration of the covenants herein contained agree as follows:

2. **ORIGINAL NOTE.** This Agreement is amending a note that exists between the Parties signed on August
 7, 2024, for the sum of Two Hundred Twenty Six Thousand Three Hundred Fifty Eight Dollars
 ($226,358) and maturing on December 31, 2025 ("Original Note").

3. **EXTENSION**.
 Under this Agreement, the Parties agree to extend the maturity date as stated in the Original
 Note to June 30, 2026 ("Extension Date").

4. **ADDITIONAL TERMS**. The Parties agree that all other terms and conditions stated in the Original Note
 shall remain in full force and effect and that there are no additional amendments.

IN WITNESS WHEREOF, the Parties have indicated their acceptance of the terms of this Agreement by there signatures below on the dates indicated.

---

| | |
|:---|:---|
| **Borrower's Signature:** | **Date:** |

---

---

| | |
|:---|:---|
| **Lender's Signature:** | **Date:** |

---

## Exhibit 10.17

**Exhibit 10.17**

**LOAN EXTENSION AGREEMENT**

**1.** **THE PARTIES.** This Loan Extension Agreement ("Agreement") made February 17, 2026
 between:

Borrower/Issuer: NovelStem International Corp. Ltd., with a mailing address of 2255 Glades Road, Suite 221A, Boca Raton, FL ("Borrower or Issuer") and

Lender/Holder: Jerry Wolasky, with a mailing address of 1360 98<sup>th</sup> Street, Bay Harbor Islands, Florida 33154, Attn: Jerry Wolasky ("Lender or Holder").

HEREINAFTER the Borrower and Lender shall be referred to together as the "Parties" and in consideration of the covenants herein contained agree as follows:

2. **ORIGINAL NOTE**. This Agreement is amending a note that exists between the Parties signed on August
 7, 2024, for the sum of Five Hundred Ninety-Five Thousand Four Hundred and Eight Dollars
 ($595,408) and maturing on December 31, 2025 ("Original Note").

3. **EXTENSION**.
 Under this Agreement, the Parties agree to extend the maturity date as stated in the Original
 Note to June 30, 2026 ("Extension Date").

4. **ADDITIONAL TERMS**. The Parties agree that all other terms and conditions stated in the Original Note
 shall remain in full force and effect and that there are no additional amendments.

IN WITNESS WHEREOF, the Parties have indicated their acceptance of the terms of this Agreement by their signatures below on the dates indicated.

---

| | |
|:---|:---|
| **Borrower's Signature:** | **Date:** |

---

---

| | |
|:---|:---|
| **Lender's Signature:** | **Date:** |

---

## Exhibit 31.1

**Exhibit 31.1**

I, Jan H. Loeb, the Principal Executive Officer and Executive Chairman of NovelStem International Corp. certify that:

&nbsp;&nbsp;&nbsp;&nbsp;1. I
 have reviewed this report on Form 10-Q of NovelStem International Corp.;

2. Based
 on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
 to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
 the period covered by this report;

3. Based
 on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
 respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in
 this report;

4. The
 registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
 (as defined in Exchange Act Rules 13a- 15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange
 Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Designed
 such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
 to ensure that material information relating to the registrant is made known to us by others within those entities, particularly
 during the period in which this report is being prepared;

(b) Designed
 such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
 supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
 for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated
 the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about
 the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
 and

(d) Disclosed
 in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's
 most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected,
 or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;5. The
 registrant's other certifying officer and l have disclosed, based on our most recent evaluation of internal control over financial
 reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing
 the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) All
 significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
 reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information;
 and

(b) Any
 fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's
 internal control over financial reporting.

---

| | |
|:---|:---|
| Dated: May 15, 2026 | Dated: May 15, 2026 |
| By: | */s/ JAN H. LOEB* |
|  | Jan H Loeb |
|  | Principal Executive Officer and Executive Chairman |

---

## Exhibit 31.2

**Exhibit 31.2**

I, Christine T. Jenkins, the Chief Financial Officer of NovelStem International Corp. certify that:

&nbsp;&nbsp;&nbsp;&nbsp;1. I
 have reviewed this report on Form 10-Q of NovelStem International Corp.;

2. Based
 on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
 to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
 the period covered by this report;

3. Based
 on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
 respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in
 this report;

4. The
 registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
 (as defined in Exchange Act Rules 13a- 15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange
 Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Designed
 such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
 to ensure that material information relating to the registrant is made known to us by others within those entities, particularly
 during the period in which this report is being prepared;

(b) Designed
 such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
 supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
 for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated
 the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about
 the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
 and

(d) Disclosed
 in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's
 most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected,
 or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;5. The
 registrant's other certifying officer and l have disclosed, based on our most recent evaluation of internal control over financial
 reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing
 the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) All
 significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
 reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information;
 and

(b) Any
 fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's
 internal control over financial reporting.

---

| | |
|:---|:---|
| Dated: May 15, 2026 | Dated: May 15, 2026 |
| By: | */s/ CHRISTINE T. JENKINS* |
|  | Christine T. Jenkins |
|  | Chief Financial Officer |

---

## Exhibit 32.1

**Exhibit 32.1**

**CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report on Form 10-Q of NovelStem International Corp. (the "Company") for the quarterly period ended March 31, 2026, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Jan H. Loeb, Principal Executive Officer and Executive Chairman of the Company, hereby certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The
 Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The
 information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of
 the Company.

---

| |
|:---|
| */s/ Jan H. Loeb* |
| Jan H. Loeb |
| Principal Executive Officer and Executive Chairman |
| May 15, 2026 |

---

## Exhibit 32.2

**Exhibit 32.2**

**CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report on Form 10-Q of NovelStem International Corp. (the "Company") for the quarterly period ended March 31, 2026, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Christine T. Jenkins, Chief Financial Officer of the Company, hereby certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The
 Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The
 information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of
 the Company.

---

| |
|:---|
| */s/ Christine T. Jenkins* |
| Christine T. Jenkins |
| Chief Financial Officer |
| May 15, 2026 |

---